By: Matt Emma
The Operating Principle: Excellence Only Matters If People Can Access It
Dr. Elisabeth Thijssen has built her career on a simple but demanding premise: scientific excellence only matters if people can access it. As Head of Science and Clinical Strategy at Neurogen Biomarking, she translates frontier research on brain health into products and programs that are clear, trustworthy, and usable. Her mandate is both exacting and pragmatic. Protect the integrity of the science. Remove friction for consumers. Align stakeholders around standards that earn confidence from clinicians and families alike.
From Curiosity to Translation: Turning Insight into Execution
Thijssen’s path began with an insight that still guides her work: actionable choices can influence brain-health trajectories. That early curiosity matured into a high-performance research career and then into a leadership philosophy centered on translation. She is explicit about priorities. Every Neurogen Biomarking offering must meet rigorous evidence thresholds, yet be delivered in a way that feels approachable and humane. In practice, this means pairing clinically grounded testing with intuitive collection methods, modern cognitive tools, and next-step guidance that connects people to expert care.
Orchestrating the Ecosystem: Aligning Partners Around a Common Standard
Her leadership is distinguished by intentional alignment and orchestration. Thijssen convenes diverse partners, laboratories, device innovators, neurologists, and community organizations, and gives them a common operating picture. She designed study frameworks, aligned on reference standards from the Alzheimer’s research community, and built governance that withstands scrutiny. Rather than championing technology in isolation, she positions each component in a responsible pathway: triage, counsel, and continue the journey with qualified experts including confirmatory testing. The result is not a single product. It is an ecosystem that scales trust.
Credible Voices, Measurable Confidence
Peers recognize both her rigor and her ability to move a field forward. Prof. Dr. Philip Scheltens, Partner and Head of the Dementia Fund at EQT Group in Amsterdam, notes, “Elisabeth has shown great leadership and deep scientific understanding while she did her PhD in Amsterdam. Really outstanding.” At the University of California, San Francisco, Assistant Professor Renaud La Joie also adds operational detail to the picture: “I worked very closely with Elisabeth when she was a PhD student… I was immediately struck by her scientific rigor and determination. She already showed fantastic leadership and collaboration skills, always building multidisciplinary teams and seeking critical feedback to improve the clinical relevance of her work.”
Operating Cadence: Build, Test, Share, Improve
Inside Neurogen, Thijssen’s impact shows up in the details: evidence maps that guide product decisions, validation plans that anticipate regulatory expectations, and community programs that meet people where they are. She has presented results on global stages and used that attention to recruit partners, strengthen advisory councils, and expand responsible access. The work is disciplined and iterative. Build. Test. Share. Improve. Repeat.
Human-Centered Strategy: Designing for Real Lives
What motivates her is not only the science but the human context around it. She brings that perspective to every decision, from study design to user experience. The outcome is a business that is as intentional as it is innovative, built to earn durable trust. In an era crowded with promises, Dr. Elisabeth Thijssen stands out for something rarer: the quiet, exacting leadership required to turn high-caliber research into solutions that reach people’s lives.
Disclaimer: The views and opinions expressed in this article are those of the author and Dr. Elisabeth Thijssen and do not necessarily reflect the official policy or position of Neurogen Biomarking or any other affiliated organizations. The information provided here is for general informational purposes only and should not be construed as medical advice. While Dr. Thijssen’s work in early Alzheimer’s detection is based on scientific research, it is important to consult with a qualified healthcare professional for personal medical advice and diagnoses. Neurogen Biomarking’s products and programs are subject to regulatory approval, and outcomes may vary based on individual circumstances.
